Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03091491 2022-06-14

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Phase 2 Terminated

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01820754 2021-02-26

TOP1201 IPI

Phase 2 Completed

24 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04250246 2020-01-31

NIBIT-ML1

Phase 2 Unknown

184 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT00527735 2018-07-18

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2 Completed

334 enrolled 29 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01471197 2014-05-12

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

CheckMate-1533

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

RAD-IO

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

G360-IIT

FLINN

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

ATLAS

NA_00092076

TOP1705

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

LN-144

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

GALAXY 3

NIVIPI-Brain

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

CheckMate 592

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

ROME

CheckMate 568

LUNGVIR

Luscid

EMERGE

Neoadjuvant Immunotherapy in Brain Metastases

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

TOP1201 IPI

NIBIT-ML1

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer